In this webinar, Dr. Jon Plehn, MD, vice president of Cardiovascular Medicine at Covance will be joined by Dr.

Industry standard timelines for end-to-end completion of a typical renal or hepatic impairment trial may be up to 18-22 months. Over the past 10 years, Covance has developed a built-for-purpose model for executing impairment studies resulting in a 36% reduction of time for end-to-end services.

? Drug development business of LabCorp ? World's most comprehensive drug development company ? Offers a consultative approach from biomarker discovery and assay development to global, multi-year trial execution in vaccines development

View this webinar to learn more about: ? Factors driving the importance of biomarkers in immuno-oncology development ? How to leverage key technologies - flow cytometry, immunohistochemistry and next-generation sequencing ? A real-world example of how to tackle the challenge of effective patient recruitment ? The best way to engage a CRO / lab partner and

Bioengineered blood vessels have great potential to improve the lives of hemodialysis patient.

What does it take to conduct an effective pediatric trial in diabetes in today's competitive landscape? From a lack of research infrastructure to the difficulties with determining inclusion/exclusion criteria, sponsors face many challenges in the process.

Gain new insights for mitigating clinical trial risk and learn how our technology can support your risk management initiatives.

This T1D webinar is hosted by Dr. Barry Goldstein (Covance) with panelists Dr. Sanjoy Dutta (JDRF) and Dr. Manasi Jaiman (Covance).

The accelerated arrival of novel vaccines and immunotherapies into the clinical space spurred the emergence of fields like personalized medicine, immune profiling and immuno-monitoring built around increasingly sophisticated testing platforms.

Hear from a panel with innovative clinical trial experience on the latest innovations in digital technologies that are changing the game in clinical trials.